Pharma's battered rep gets a modest facelift in the latest industry ratings from Gallup — but it's still looking pretty bad
When the pandemic started up earlier this year, quite a few pharma execs felt it was the perfect opportunity to mend fences with the American …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
